Combination of lenalidomide or pomalidomide and cd38 antibody-attenuated interferon-alpha constructs, and the use thereof

• 收藏
• 分享

专利权人:

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD.

发明人:

Pogue, Sarah,Wilson, David,Doyle, Anthony,Behrens, Collette

申请号：

NZ72548715

公开号：

NZ725487A

申请日:

2015.05.01

申请国别(地区):

NZ

年份:

2020

代理人:

摘要：

Methods for cancer treatment include administering to a cancer patient an anti- CD38 antibody-attenuated human IFN alpha-2b construct and lenalidomide or pomalidomide. Tumors that may be treated according to these methods include tumors which comprise CD-38 expressing tumor cells, including B-cell lymphoma, multiple myeloma, non-Hodgkin’s lymphoma, chronic myelogenous leukemia, chronic lymphocytic leukemia, and acute lymphocytic leukemia.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/